Autoantibodies Directed Against Interferon Alpha, Nuclear Antigens, Cardiolipin, and Beta 2 Glycoprotein 1 Are Not Induced By SARS-CoV-2 or Associated with Long COVID.
Adam Epstein-Shuman, Joanne H Hunt, Patrizio Caturegli, Patrick Winguth, Reinaldo E Fernandez, Gracie M Rozek, Xianming Zhu, Nicholas A DiRico, Armaan Jamal, Yu-Hsiang Hsieh, Yukari C Manabe, Andrew D Redd, Steven J Reynolds, Annukka A R Antar, Oliver Laeyendecker
{"title":"Autoantibodies Directed Against Interferon Alpha, Nuclear Antigens, Cardiolipin, and Beta 2 Glycoprotein 1 Are Not Induced By SARS-CoV-2 or Associated with Long COVID.","authors":"Adam Epstein-Shuman, Joanne H Hunt, Patrizio Caturegli, Patrick Winguth, Reinaldo E Fernandez, Gracie M Rozek, Xianming Zhu, Nicholas A DiRico, Armaan Jamal, Yu-Hsiang Hsieh, Yukari C Manabe, Andrew D Redd, Steven J Reynolds, Annukka A R Antar, Oliver Laeyendecker","doi":"10.1016/j.ijid.2024.107289","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Autoantibodies (AAbs) directed against interferon alpha (aIFNα), nuclear antigens (ANAs), cardiolipin (aCL), and beta 2 glycoprotein 1 (aβ2GP1), have been demonstrated to significantly correlate with the severity of acute COVID-19. However, whether SARS-CoV-2 infection induces these AAbs and whether they are associated with long COVID remains unclear.</p><p><strong>Methods: </strong>The potential induction of aIFNα, ANAs, aCL, and aβ2GP1 by SARS-CoV-2 was assessed by measuring these AAbs in 224 pre- and post-infection paired serum samples from the Johns Hopkins Hospital Emergency Department (JHHED). The relationship between these AAbs and long COVID was assessed using 60 serum samples from participants in the Outpatient SARS-CoV-2 Mild and Asymptomatic Infection Response and Transmission (OutSMART) study.</p><p><strong>Results: </strong>We found no evidence that these AAbs were induced in the JHHED cohort and no significant difference in their prevalence between patients with (n=30) and without (n=30) long COVID in the OutSMART cohort.</p><p><strong>Conclusions: </strong>These findings do not support the hypotheses that SARS-CoV-2 induces these AAbs or that they are related to long COVID.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":4.8000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ijid.2024.107289","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Autoantibodies (AAbs) directed against interferon alpha (aIFNα), nuclear antigens (ANAs), cardiolipin (aCL), and beta 2 glycoprotein 1 (aβ2GP1), have been demonstrated to significantly correlate with the severity of acute COVID-19. However, whether SARS-CoV-2 infection induces these AAbs and whether they are associated with long COVID remains unclear.
Methods: The potential induction of aIFNα, ANAs, aCL, and aβ2GP1 by SARS-CoV-2 was assessed by measuring these AAbs in 224 pre- and post-infection paired serum samples from the Johns Hopkins Hospital Emergency Department (JHHED). The relationship between these AAbs and long COVID was assessed using 60 serum samples from participants in the Outpatient SARS-CoV-2 Mild and Asymptomatic Infection Response and Transmission (OutSMART) study.
Results: We found no evidence that these AAbs were induced in the JHHED cohort and no significant difference in their prevalence between patients with (n=30) and without (n=30) long COVID in the OutSMART cohort.
Conclusions: These findings do not support the hypotheses that SARS-CoV-2 induces these AAbs or that they are related to long COVID.
期刊介绍:
International Journal of Infectious Diseases (IJID)
Publisher: International Society for Infectious Diseases
Publication Frequency: Monthly
Type: Peer-reviewed, Open Access
Scope:
Publishes original clinical and laboratory-based research.
Reports clinical trials, reviews, and some case reports.
Focuses on epidemiology, clinical diagnosis, treatment, and control of infectious diseases.
Emphasizes diseases common in under-resourced countries.